PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO - ND

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO0 个研究点开始时间: 2009年4月22日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•no evidence of clinical problems with influence on blood crasis (i.e. Infections, bleedings, surgical procedures) in the last 6 months
•- stable hemoglobin values into NKF-DOKI range (11-12g/dl) or more for minimum three months before study inclusion
•epoetin alfa, epoetin beta, darbopoetin therapy with modifications inferior to 25% of the dose for minimum three months before study inclusion
•therapy with ferrum or B12 vitamin or folinic acid administration without any modification for minimum three months before study inclusion
•last available PTHi value < 500pg/ml
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Drug controindications to MIRCERA: ipersensivity reactions to drug formulation or non controlled arterial hypertension
•Neoplasia or drug therapy or radioteraphy for previous neoplasia

发起方

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO